汇宇制药：2025年度预亏2400万元至2900万元

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) expects a significant net loss for the fiscal year 2025, indicating a challenging financial outlook for the company [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company to range from a loss of 29 million yuan to a loss of 24 million yuan for 2025, representing a year-on-year decline of 108.91% to 107.38% compared to the previous year [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 78 million yuan and 93 million yuan, reflecting a year-on-year change of a decrease of 15.33% to an increase of 0.96% [1] Investment Impact - The company’s investment in Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd. is set to be listed on the Hong Kong Stock Exchange on August 20, 2024, under the stock code 02410.HK [1] - The fair value change loss due to the fluctuation in the stock price of the invested enterprise during the reporting period amounts to 173 million yuan [1]